Sign up Australia
Proactive Investors - Run By Investors For Investors

Medlab Clinical Ltd advances research amid nutraceuticals revenue growth

Three studies are the focus as the company targets chronic illnesses, including cancer, using a pipeline that includes cannabis products and probiotics.
Stacks of Australian hundred dollar notes
Medlab’s ahead-of-schedule clinical programs have contributed to its cash burn

Medlab Clinical Ltd (ASX:MDC) has increased annual revenues by 25% to $5.5 million while increasing its net tangible assets per security by 518% to 10.5 cents.

The results came on the back of a 25% increase in net loss to $4.6 million.

Medlab reported the net loss increase was due to the accelerated costs of its research projects, with some up to 18 months ahead of schedule, and NanaBis costs related to the Federal Government’s Special Access Scheme (SAS).

Cash receipts were up 47% as the company ended June 30 with a $20.3 million cash balance.


Financial year standouts

Medlab managing director Sean Hall reported the company made a number of achievements in the 2017-18 financial year in its nutraceutical business and its research.

These included receiving a licence to sell or supply a schedule 8 or schedule 9 drugs which was limited to cannabis and its derivatives.

The company also progressed its Phase 1/2a clinical trial of cannabis cannabidiol/tetrahydrocannabinol (CBD/THC) therapy NanaBis in seriously ill cancer patients at Sydney’s Royal North Shore Hospital, with the trial now underway.

The product was licensed for supply, along with fellow cannabis CBD product NanaBidial, through the Australian Government’s access scheme SAS.

Positive “exciting” data began to be returned from doctors prescribing NanaBis.

READ: Medlab Clinical to begin clinical trial of nutraceutical product in oncology patients

Another trial, Phase 2a clinical trial of NRGBiotic probiotic in depression, was also underway, at Queensland University of Technology Brisbane.

Medlab’s nutraceutical business continuing to grow by gaining recognition in professional pharmacy spaces.

The company upped revenues in the complementary business to its therapeutics program by 26% while keeping a lid on operating expenses.

Medlab chairman Michael Hall reported a third trial was being prepared for, a Phase 2a study of the T2Biotc in obese and diabetic patients, as a follow-on to the completed Phase1a trial.

READ: Medlab Clinical substantial shareholder Farjoy demonstrates confidence in medical research strategy

Managing director Hall said: “Medlab’s strategy is to pursue meaningful discussions with major pharmaceutical companies to have them appreciate our potential, leading to possible favourable financial outcomes for shareholders.

“Events during these past three years have supported our concentration on chronic illnesses.”

He pointed to the overuse of opioids, and deaths from their use, and the costs of depression, mental illness and obesity as illnesses and crises the company could respond to.

Hall said the company had made good progress towards achieving the goals it set at the time of listing on the Australian Securities Exchange.

READ: Medlab Clinical receives large shipment of cannabis oil for human trials

He argued the company’s research was a market differentiator that set Medlab apart from other organisations.

Hall said: “R&D is the driver of potential from its focus on chronic diseases while nutraceutical sales assist cash flow funding of Medlab’s programs.”

He highlighted the company had received human ethics approval for a trial of Medlab’s commercialised MultiBiotic product as a treatment for mucositis.

Mucositis is the painful condition where the mucous membranes lining the digestive tract become inflamed and ulcerate, usually after chemotherapy or radiotherapy treatment for cancer.

View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use